Jubilant Pharmova Ltd.

₹999.3

-29.5 (-2.9%)

JUBLPHARMA Share Price

Pharmaceuticals & Biotechnology

As on October 1, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 15,938.5 Cr

P/E Ratio39.62

Dividend Yield0.5 %

Trendline Performance

We are partnered with TradingView, a global leader in charting and market analysis. Access real-time stock data, explore the powerful Stock Screener , and uncover insights with multiple tools designed for traders.

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	1,041.74	Bearish
10-DMA	1,051.61	Bearish
20-DMA	1,019.65	Bearish
50-DMA	957.2	Bullish
100-DMA	970.91	Bullish
200-DMA	957.1	Bullish

Historical Performance

1 Year

-10.2%

3 Years

129.6%

5 Years

59%

10 Years

62.7%

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022
Net Sales	82,796	72,345	67,029	62,817	61,302
Total Expenditure	70,198	60,608	58,021	55,055	49,738
Other Income	660	568	687	383	113
Operating Profit	13,258	12,305	9,695	8,145	11,676
Interest	2,118	2,403	2,723	1,882	1,455
Depreciation	4,404	3,686	3,819	5,540	3,817
Profit Before Tax	6,141	9,806	1,705	278	6,304
Consolidated Net Profit	3,985	8,394	771	-610	4,139
Adjusted EPS	25	53	5	-4	26

Compounded Sales Growth

10 Years:7.6

5 Years:6.3

3 Years:5.7

TTM:2.7

Compounded Profit Growth

10 Years:0.3

5 Years:-13.8

3 Years:17.8

TTM:-13.8

Stock Price CAGR

10 Years:5

5 Years:9.7

3 Years:31.9

TTM:-10.2

Return on Equity

10 Years:37

5 Years:26

3 Years:4.9

last year:25.2

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022
Share Capital	158	158	158	159	159
Total Reserves	70,578	62,243	54,036	53,772	52,990
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	56,311	40,958	40,057	37,650	29,216
Other Current Liabilities	10,279	8,440	7,328	5,521	8,385
Short Term Borrowings	1,625	2,190	1,965	2,583	640
Total Liabilities	1,52,656	1,24,991	1,13,158	1,09,292	98,296
Capital Work in Progress	29,615	27,147	12,523	7,733	2,918
Long Term Loans & Advances	660	541	1,919	1,615	1,176
Currents Investments	---	---	---	---	---
Short Term Loans and Advances	3,210	2,463	2,280	2,713	2,312
Total Current Assets	41,093	35,098	36,322	37,624	35,092
Total Assets	1,52,656	1,24,991	1,13,158	1,09,292	98,296
Adjusted Book Value	448	395	343	339	334

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a high PE of 39.62, indicating expensive valuation or elevated growth expectations.
Over the last three years, the stock delivered a strong 3-year price CAGR of 31.8%, indicating sustained price appreciation.
The stock carries a low beta of 0.6, suggesting lower volatility than the broader market.
In the last financial year, the company reported an EBITDA of ₹13258 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹82796 million, indicating a large and established business.

Investment Calculator

Investment Amount:₹

Investment Amount: ₹ 1000000

Current Value: ₹ 892710.4

No. of Shares: 893 (Approx)

Performance:-10.7%

-107289.6

NIFTY Performance: -9.7%

1 day Top Gainers